Media stories about Otonomy (NASDAQ:OTIC) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Otonomy earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 48.6805316062806 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s analysis:
- Otonomy, Inc. (OTIC) CEO David Weber on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Otonomy (OTIC) Reports Q2 Loss, Misses Revenue Estimates (finance.yahoo.com)
- Otonomy (OTIC) Issues Earnings Results, Misses Expectations By $0.06 EPS (americanbankingnews.com)
- Recent Technical Snapshot: Otonomy, Inc. (OTIC) is now worth at $3.75 (topdesertsafari.com)
- Otonomy, Inc. (OTIC) stock price jumped 13.64% (topdesertsafari.com)
OTIC stock remained flat at $$3.50 during trading on Friday. 139,044 shares of the company’s stock traded hands, compared to its average volume of 154,915. Otonomy has a 12-month low of $2.80 and a 12-month high of $21.15. The company has a market capitalization of $107.21 million, a price-to-earnings ratio of -1.18 and a beta of 3.03.
A number of analysts recently issued reports on the stock. ValuEngine upgraded shares of Otonomy from a “sell” rating to a “hold” rating in a research note on Monday, June 4th. Zacks Investment Research upgraded shares of Otonomy from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Saturday, April 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $8.95.
Otonomy Company Profile
Otonomy, Inc, a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus.
Featured Story: Investing in Growth Stocks
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.